PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Documentary highlights new targets to potentially treat motor neurone disease

The terminal condition currently affects around 5,000 people in the UK.

A new documentary has highlighted the discovery of a promising new target for new treatments of motor neurone disease (MND) made by researchers at University College London (UCL).

The short documentary, Turning the Tide, was funded as part of LifeArc’s MND Translational Fund and other MND charities, as well as the MND scientific community.

Currently affecting around 5,000 people in the UK, MND is a terminal condition that affects the nerve cells – motor neurons – in the brain and spinal cord, which control muscle movement.

Individuals with MND slowly and progressively lose the ability to walk, talk, eat and breathe as the cells die and muscles in the body start to waste away.

The new documentary provides insight into what it is like for those living with MND as well as their hopes for ongoing research in the field.

Researchers at the UCL Queen Square Institute of Neurology identified how the loss of a protein from the nucleus of motor neurons, TDP-43, corrupts the genetic instructions required to produce another key protein, UNC13A, which impacts the normal functioning of the cells.

Furthermore, researchers went on to identify how antisense oligonucleotide technology, a form of gene therapy treatment, could block this process and potentially slow down the profession of MND.

Backed by a £500,000 award from LifeArc, the Motor Neurone Disease Association and the My Name’5 Doddie Foundation, the potential treatment works by targeting the cause of the disease at a genetic level by restoring the production of the UNC13A protein.

They aim to secure further funding to advance the UCL research team and kickstart the process of getting a treatment clinically tested for people living with MND.

Stéphane Maikovsky, interim chief executive officer of LifeArc, said: “Funding pioneering research into the disease… is critical to unlock desperately needed treatments for patients.

“This discovery marks a significant advancement in our understanding of MND and suggests an exciting target for future treatments.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026